Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients

This is the authors' abstract. We don't add key points for this paper.

OBJECTIVES: To assess the efficacy and the risk of sofosbuvir-daclatasvir treatment among kidney transplant recipients (KTRs) with chronic hepatitis C virus (HCV) infection. METHODS: A real-life retrospective cohort analysis was performed on KTRs treated with sofosbuvir-daclatasvir at our center between January 2016 and March 2018. We collected data from 19 KTRs (13 males; age 48.3 ± 9.6 years; HCV genotype I, n = 16; chronic active hepatitis B coinfection, n = 8). Virological and clinical data were assessed. RESULTS: Overall, 100% of the patients had achieved a sustained virological response 12 weeks after treatment (SVR12). Their liver function improved notably, with a significant decline in the serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (ALT 34.8 ± 18.6 IU/L pre-treatment and 15.0 ± 6.8 IU/L post-treatment, P = 0.0003; AST: 35.05 ± 18.1 IU/L pre-treatment and 19.1 ± 7.0 post-treatment, P = 0.001). A significant amelioration was observed in patients with proteinuria (n = 12) (0.95 [0.35-3.31] g/g at baseline to 0.39 [0.27-1.02] g/g post-therapy, P = 0.048). The serum creatinine, eGFR, and tacrolimus levels were stable during therapy. CONCLUSION: The preliminary data demonstrated that sofosbuvir-daclatasvir was highly effective in treating HCV infection in KTRs with acceptable tolerance.